DAX ®13.282,72+0,46%TecDAX ®3.049,40+0,31%Dow Jones28.135,38+0,01%NASDAQ 1008.487,71+0,25%
finanztreff.de

PRESS RELEASE: MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

| Quelle: Dow Jones Newsw... | Lesedauer etwa 8 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting (news with
additional features)

2019-11-06 / 22:02
The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, November 6, 2019

*MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting *

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR)
today announced presentation of so far unpublished data on tafasitamab, its
proprietary key asset and investigational hemato-oncological drug candidate,
at the upcoming 61th American Society of Hematology (ASH) 2019 Annual
Meeting, taking place from December 7-10, 2019 in Orlando, Florida.

This year, overall four abstracts feature the clinical development of
tafasitamab in diffuse large B-cell lymphoma (DLBCL) as well as other blood
cancer indications. In addition, three abstracts feature preclinical data.

Abstracts on the clinical development of tafasitamab in DLBCL:

? Subgroup analysis from the L-MIND trial, a phase 2 study assessing
tafasitamab in combination with lenalidomide in patients with relapsed or
refractory DLBCL

? Trial in progress update for the First-MIND trial, an open label,
randomized study in patients with newly diagnosed DLBCL

Abstracts on the clinical development of tafasitamab in other blood cancer
indications:

? Results from the COSMOS trial, assessing tafasitamab in combination with
idelalisib or venetoclax in patients with relapsed of refractory chronic
lymphocytic leukemia (CLL)

? Final analysis and long term follow-up of tafasitamab monotherapy in
patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Preclinical abstracts on in vitro studies:

? Study investigating gamma delta T cells and allogeneic activated NK
cells as effector cells for tafasitamab

? Study investigating the influence of tafasitamab on CAR-T cell activity

? Study investigating tumor-associated macrophages as effector cells for
tafasitamab

"We are excited to present a number of important updates on our
investigational compound tafasitamab at this year's ASH," said Dr. Malte
Peters, Chief Development Officer of MorphoSys AG. "The seven accepted
abstracts provide insights into our scientific and clinical activities to
evaluate the efficacy and safety of tafasitamab. The data highlight our
commitment to patients with high unmet medical needs."

MorphoSys will meet ASH attendees at the Orange County Convention Center, at
Booth #1261.

*Details about MorphoSys's abstracts accepted for presentation at ASH 2019:*

_Subgroup analysis from L-MIND, a Phase II Study of Tafafsitamab (MOR208)
Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse
Large B-Cell Lymphoma_

Abstract publication number: 1582
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive
B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical Trials:
Poster I
Session date and time: Saturday, December 7th, 2019; 9:00 am - 7:30 pm ET
Poster presentation time: 5:30 pm - 7:30 pm ET

_A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary
Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition
to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma:
The First-MIND Trial_

Abstract publication number: 2877
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive
B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical Trials:
Poster II
Session date and time: Sunday, December 8th, 2019; 9:00 am - 8:00 pm ET
Poster presentation time: 6:00 pm - 8:00 pm ET

_Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination
with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK
Inhibitor Therapy (COSMOS Trial)_

Abstract publication number: 1754
Session: 642. CLL: Therapy, excluding Transplantation: Poster I
Session date and time: Saturday, December 7th, 2019; 9:00 am - 7:30 pm ET
Poster presentation time: 5:30 pm - 7:30 pm ET

_A Phase IIa, Open-label, Multicenter Study of Single-Agent Tafasitamab
(MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or
Refractory B-Cell Non-Hodgkin's Lymphoma: Long-term Follow-up, Final
Analysis_

Abstract publication number: 4078
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive
B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical Trials:
Poster III
Session date and time: Monday, December 9th, 2019; 10:00 am - 8:00 pm ET
Poster presentation time: 6:00 pm - 8:00 pm ET

_Targeting of CD19 by Tafasitamab Does Not Impair CD19 Directed Chimeric
Antigen Receptor T Cell Activity In Vitro_

Abstract publication number: 2859
Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents:
Poster II
Session date and time: Sunday, December 8th, 2019; 9:00 am - 8:00 pm ET
Poster presentation time: 6:00 pm - 8:00 pm ET

_Functional Characterization of Gamma Delta T Cells and Allogeneic Activated
NK Cells as Effector Cells for Tafasitamab (MOR208)_

Abstract publication number: 3801
Session: 605. Molecular pharmacology drug resistance - lymphoid and other
diseases: Poster III
Session date and time: Monday, December 9th, 2019; 10:00 am - 8:00 pm ET
Poster presentation time: 6:00 pm - 8:00 pm ET

_Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent
Cellular Phagocytosis Alone or in Combination with Lenalidomide_

Abstract publication number: 4064
Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents:
Poster III
Session date and time: Monday, December 9th, 2019; 10:00 am - 8:00 pm ET
Poster presentation time: 6:00 pm - 8:00 pm ET

The abstracts will also be available online in a supplemental issue of
_Blood_. Additional information, including the abstracts, can be found in
the online meeting program of the American Society of Hematology.

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
exceptional, innovative therapies for patients suffering from serious
diseases. The focus is on cancer. Based on its leading expertise in
antibody, protein and peptide technologies, MorphoSys, together with its
partners, has developed and contributed to the development of more than 100
product candidates, of which 29 are currently in clinical development. In
2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis,
became the first drug based on MorphoSys's antibody technology to receive
regulatory approval. The Company's most advanced proprietary product
candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough
therapy designation for the treatment of patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany,
the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US
Inc., has approximately 405 employees. More information at
https://www.morphosys.com [1].

HuCAL(R), HuCAL GOLD(R) , HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio
Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys
Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

_MorphoSys forward looking statements_
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, including the expectations regarding the
progression of and upcoming data presentations from the clinical development
of tafasitamab in combination with lenalidomide in the L-MIND study in r/r
DLBCL, the clinical development of tafasitamab in combination with
idelalisib or venetoclax in the COSMOS study in r/r CLL/SLL, the clinical
development of tafasitamab in patients with newly diagnosed DLBCL as well as
preclinical studies investigating tafasitamab. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the
date of this release and involve known and unknown risks and uncertainties,
which might cause the actual results, financial condition and liquidity,
performance or achievements of MorphoSys, or industry results, to be
materially different from any historic or future results, financial
conditions and liquidity, performance or achievements expressed or implied
by such forward-looking statements. In addition, even if MorphoSys' results,
performance, financial condition and liquidity, and the development of the
industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are MorphoSys'
expectations regarding the progression of and upcoming data presentations
from the clinical development of tafasitamab in combination with
lenalidomide in the L-MIND study in r/r DLBCL, the clinical development of
tafasitamab in combination with idelalisib or venetoclax in the COSMOS study
in r/r CLL/SLL, the clinical development of tafasitamab in patients with
newly diagnosed DLBCL as well as preclinical studies investigating
tafasitamab, MorphoSys' reliance on collaborations with third parties,
estimating the commercial potential of its development programs and other
risks indicated in the risk factors included in MorphoSys's Annual Report on
Form 20-F and other filings with the US Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
MorphoSys expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the

(MORE TO FOLLOW) Dow Jones Newswires

November 06, 2019 16:02 ET ( 21:02 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 51 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen